Quick Takeaways
- Commodore Capital LP filed SCHEDULE 13G for Cardiff Oncology, Inc. Common Stock, $0.0001 par value (CRDF).
- Disclosed ownership: 8.1%.
- Date of event: 10 Dec 2024.
Commodore Capital LP - 10 Dec 2024 SCHEDULE 13G Report for Cardiff Oncology, Inc. Common Stock, $0.0001 par value (CRDF)
- Filing Manager
- Commodore Capital LP
- Reporting Manager
- COMMODORE CAPITAL LP
- Symbol
- CRDF
- Shares outstanding
- 66,476,741 shares
- Disclosed Ownership
- 5,384,616 shares
- Ownership
- 8.1%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Dec 2024, 16:06:19 UTC
- Date of event
- 10 Dec 2024
- Next filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Commodore Capital LP disclosed 8.1% ownership in Cardiff Oncology, Inc. Common Stock, $0.0001 par value (CRDF) on 10 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Dec 2024, 16:06.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| COMMODORE CAPITAL LP | 8.1% | 5,384,616 | 0 | 5,384,616 | /s/ Michael Kramarz | Michael Kramarz, Managing Partner | |
| Commodore Capital Master LP | 8.1% | 5,384,616 | 0 | 5,384,616 | /s/ Michael Kramarz | Michael Kramarz, Authorized Signatory |